Viatris (NASDAQ:VTRS) shares reached the highest level since late February on Thursday after the maker of the anxiety drug Xanax reported better-than-expected financials for Q3 2024 and set its revenue outlook ahead of consensus.

The Pennsylvania-based drugmaker, which formed in 2020

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.